From November 5 to 10, the 9th China International Import Expo (CIIE) is being held at the National Exhibition and Convention Center in Shanghai.

On November 5, JD Health (HKEX: 06618) CEO Cao Dong stated during the CIIE that by revenue scale, JD Health has maintained its position as the largest pharmaceutical retail platform in China for multiple consecutive years. It is reported that in the first three quarters of 2026, JD Health launched more than 100 new drugs online, surpassing the total for all of last year, covering areas such as oncology, dermatology, chronic diseases, GLP-1 weight-loss and metabolic treatments, and women's health.

Cao Dong noted that when global new drugs enter China and seek an online launch platform, JD Health is increasingly the first choice that comes to mind. It is understood that since the beginning of this year, multiple new drugs have chosen to debut on JD Health. For example, Takeda's Ozeray for the treatment of narcolepsy was exclusively launched across all platforms on October 15, and after the launch, patients can use JD Health's internet hospital for online follow-up consultations, prescription renewals, and medication purchases without repeatedly visiting hospitals.

"After the launch, how to ensure patients can actually get the medication is the key," Cao Dong said. "Buying global quality drugs on JD is not a slogan — it means ensuring every new drug, from approval to reaching the patient's hands, has a link that holds and runs smoothly. After the launch, every step — prescriptions, pharmacies, follow-ups — needs someone to handle it. JD Health relies on omnichannel fulfillment, full-cycle services, and all-scenario AI. The CIIE is just the starting point; going forward, it still needs to be validated through daily fulfillment."